Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives
L Ceolin, MA da Silveira Duval… - Endocrine-related …, 2019 - erc.bioscientifica.com
Medullary thyroid carcinoma (MTC) is a rare type of tumor that originates from thyroid C cells
and accounts for 2–4% of all malignant thyroid neoplasms. MTC may occur sporadically or …
and accounts for 2–4% of all malignant thyroid neoplasms. MTC may occur sporadically or …
Multiple endocrine neoplasia type 2: A review
JS Mathiesen, G Effraimidis, M Rossing… - Seminars in cancer …, 2022 - Elsevier
Multiple endocrine neoplasias are rare hereditary syndromes some of them with malignant
potential. Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant hereditary …
potential. Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant hereditary …
Overview of the 2022 WHO classification of familial endocrine tumor syndromes
This review of the familial tumor syndromes involving the endocrine organs is focused on
discussing the main updates on the upcoming fifth edition of the WHO Classification of …
discussing the main updates on the upcoming fifth edition of the WHO Classification of …
Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors
SA Wells - Endocrine-Related Cancer, 2018 - erc.bioscientifica.com
Medullary thyroid carcinoma (MTC), a tumor derived from the neural crest, occurs either
sporadically or as the dominant component of the type 2 multiple endocrine neoplasia …
sporadically or as the dominant component of the type 2 multiple endocrine neoplasia …
GLOBAL ENDOCRINOLOGY: Geographical variation in the profile of RET variants in patients with medullary thyroid cancer: a comprehensive review
RMB Maciel, AL Maia - European Journal of Endocrinology, 2022 - academic.oup.com
Genetic variability in humans is influenced by many factors, such as natural selection,
mutations, genetic drift, and migrations. Molecular epidemiology evaluates the contribution …
mutations, genetic drift, and migrations. Molecular epidemiology evaluates the contribution …
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations
ZX Wang, QQ Li, J Cai, JZ Wu, JJ Wang… - Journal of Medicinal …, 2024 - ACS Publications
Over the past decades, the role of rearranged during transfection (RET) alterations in
tumorigenesis has been firmly established. RET kinase inhibition is an essential therapeutic …
tumorigenesis has been firmly established. RET kinase inhibition is an essential therapeutic …
[HTML][HTML] Dermatologic manifestations of endocrine disorders
Endocrine disorders are known to involve all organ systems of the body, including the skin.
The cutaneous manifestations of endocrine disorders can range from common findings such …
The cutaneous manifestations of endocrine disorders can range from common findings such …
Primary Localized Cutaneous Amyloidosis in Central Europe: A Retrospective Monocentric Study on Epidemiology and Therapy
Amyloid deposits can be the cause of many chronic diseases. Primary localized cutaneous
amyloidosis (PLCA) is a chronic dermatologic condition with amyloid deposits in the …
amyloidosis (PLCA) is a chronic dermatologic condition with amyloid deposits in the …
Primary localized cutaneous amyloidosis of keratinocyte origin: an update with emphasis on atypical clinical variants
L Hamie, I Haddad, N Nasser, M Kurban… - American Journal of …, 2021 - Springer
Amyloid is a protein derived from at least 20 different substances. Once misfolded, it results
in a group of cutaneous and systemic conditions. Primary localized cutaneous amyloidosis …
in a group of cutaneous and systemic conditions. Primary localized cutaneous amyloidosis …
Advances and controversies in the management of medullary thyroid carcinoma
Tyrosine kinase inhibitors are effective therapeutic agents for the treatment of progressive
MTC. Nevertheless, it is not clear who will benefit the most from therapy, and the decision …
MTC. Nevertheless, it is not clear who will benefit the most from therapy, and the decision …